BiotechTube

SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBO

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Active Psoriatic Arthritis

Conditions

Active Psoriatic Arthritis

Trial Timeline

Apr 19, 2017 → Sep 24, 2019

NCT ID
NCT02980692

About SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBO

SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBO is a phase 2 stage product being developed by Sun Pharmaceutical for Active Psoriatic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02980692. Target conditions include Active Psoriatic Arthritis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02980692Phase 2Completed

Competing Products

20 competing products in Active Psoriatic Arthritis

See all competitors
ProductCompanyStageHype Score
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
mirabegron + solifenacinAstellas PharmaApproved
85
CDP870Astellas PharmaPhase 3
77
Mirabegron + PlaceboAstellas PharmaApproved
85
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
BetanisAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaApproved
85
SolifenacinAstellas PharmaPhase 2
52
Mirabegron + Tolterodine ERAstellas PharmaApproved
85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
23
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
warfarin + YM178Astellas PharmaPhase 1
33
Solifenacin succinateAstellas PharmaPhase 3
77
solifenacin succinate + tolterodineAstellas PharmaPhase 3
77

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85